introduction
The results of treatment of patients with aggressive T-cell lymphomas are generally worse than those for patients with diffuse large B-cell lymphomas [1] [2] [3] . In particular, most aggressive peripheral T-cell lymphoma unspecified (PTCLU) patients are traditionally treated with an anthracyclinecontaining regimen and complete response (CR; CR requires the complete disappearance of all detectable clinical and radiographic evidence of disease, the disappearance of all disease-related symptoms, and normalization of biochemical abnormalities) rates of 50%-70% have been reported [4] [5] [6] . However, the 5-year overall survival for PTCLU patients was 20%-30%. This did not significantly differ by the type of chemotherapy administered. The effects of high-dose therapy and stem-cell transplantation at the time of first CR were not easily evaluated due to difficult comparisons; however, stemcell transplant at the time of relapse did offer an advantage over salvage chemotherapy.
Regarding the cutaneous T-cell lymphoma and in particular mycosis fungoides (MF), the use of systemic chemotherapy as a first-line treatment should be restricted with few exceptions to advanced/aggressive MF patients [7] [8] [9] . The choice of treatment is often determined by institutional experience, particularly as there is a paucity of data from phase III trials and a lack of consensus concerning treatment of the later stages of MF. A strict rule is definitely nonappropriate in this regards; a careful and balanced evaluation of specific diagnosis, tumor load, cutaneous lesions' features, age, general conditions, and immune status of the patients is obviously the standard to date.
Among the several second-line and experimental drugs, gemcitabine should be considered one of the most suitable options to date for pretreated PTCLU and MF patients. Gemcitabine has been demonstrated to be an effective monotherapy with a 60%-70% overall response rate (ORR) in patients with advanced disease and heavily pretreated [10] [11] [12] [13] . In addition, there are also interesting data in untreated patients [14] and even some data describing the efficacy of gemcitabine combinations in patients with T-cell lymphoma [15] [16] [17] [18] .
As well known, it is difficult to find in literature the longterm outcome regarding the efficacy of a single-agent drug in pretreated patients and, in particular, in rare diseases such as Tcell lymphomas. In this study, we report the long-term update of the outcome of 39 heavily pretreated T-cell lymphoma patients after salvage treatment with gemcitabine. [19] ; relapsed or refractory disease after at least two conventional therapeutic approaches (chemotherapy and/or radiotherapy); age ‡18 years; and World Health Organization (WHO) performance status of two or less. The extent of the disease was determined before and at the end of the treatment, as well as during the follow-up, by complete skin examination, physical examination, laboratory tests, computed tomography (CT) scanning of the chest, abdomen, and pelvis and bone marrow biopsy (it was repeated at the end of the treatment only if it was positive at baseline).
patient population
Detailed patient characteristics are listed in Table 1 . Nineteen of 39 patients had a diagnosis of MF and 20 of PTCLU. All patients with MF were classified with T3 or T4, N0, and M0 disease [20] using the tumor-nodemetastasis classification for T-cell lymphomas and patients with PTCLU were classified with stage III-IV disease according to the Ann Arbor staging system [21] . The median age of the patients was 54 years (range 32-78 years); 29 patients were male and 10 were female. The median number of prior treatments was three (range 2-8).
treatment protocol
Gemcitabine hydrochloride (Gemzar; Eli Lilly, Indianapolis, IN) was supplied as a lyophilized powder. The drug was diluted in normal saline solution and administered i.v. over 30 min. Gemcitabine was given to all patients on days 1, 8, and 15 of a 28-day schedule at a dose of 1200 mg/m 2 per day for a total of three to six cycles (8 patients had three courses, 2 patients had four courses, and 20 patients underwent upto six courses). All cycles were delivered on an outpatient basis.
response evaluation
Tumor response was assessed by measuring the reduction in skin lesions on physical examination and the reduction in lymph node infiltration by CT scan. Response was defined according to previously reported international criteria [22] .
Patients were evaluated by weekly history and physical examinations, complete blood counts, and chemistry profiles. All signs, symptoms, or laboratory abnormalities were assessed using WHO criteria for toxic effects.
results response
Clinical results are summarized in Table 2 . The ORR [CR + partial response (PR; PR requires a 50% decrease or more in sum of the products of the greatest diameters of the six largest dominant nodes or nodal masses. There should be no increase in the size of the other nodes, liver or spleen)] was 51% (20 of 39 patients); the CR and PR rates were 23% (9 of 39 patients) and 28% (11 of 39 patients), respectively. According to the histologic subtypes, patients with MF had a CR rate of 16% (3 of 19 patients) compared with 30% (6 of 20 patients) of the patients with PTCLU. Patients with MF had a PR rate of 31.5% (6 of 19 patients) compared with 25% (5 of 20 patients) of the patients with PTCLU.
Among the nine CRs, five were histologically confirmed when reevaluated with a local biopsy; seven of these patients (including all histologic CRs) were still in remission with a median time of 34 months (range 15-120 months) from the end of gemcitabine. The other two patients relapsed after 7 and 10 months, respectively. The former was a systemic PTCLU patient who presented a nodal relapse in several sites; the latter was an MF patient who showed a diffuse skin relapse.
Regarding the seven long-term continuous complete responses (CCRs) ( Table 3) , two patients had MF and five patients had PTCLU (three with systemic disease and with isolated skin involvement). Table 3 summarizes the characteristics of these patients. The Figure 1 explains the algorithm during the outcome of all nine CRs.
treatment toxicity
Gemcitabine was generally well tolerated, and all of the responding patients completed the treatment. With regard to hematologic toxicity, no WHO grade 3-4 was observed. Grade 1-2 neutropenia was reported in 15 (38.5%) patients, and grade 1-2 thrombocytopenia was recorded in 18 (46%) patients; the duration of thrombocytopenia was <2 weeks. Concerning the non-hematologic toxicity, hepatic toxicity (transient increase of liver enzymes) was reported in 14 (36%) patients (in all cases, it was grade 1 or 2, but one patient had grade 3). No patient experienced complete alopecia, no nausea and emesis was reported, and none of the patients died of complications related to gemcitabine.
discussion
In the last years, many steps forward have been made in the classification and treatment of peripheral T-cell lymphoma and MF. Several initiatives are going on to clearly and distinctly categorize the T-cell lymphomas in order to define appropriate therapies for each disease entity. New studies are required to assess gene expression profiling with comparative genomic hybridization and detailed phenotypic, cytogenetic, and molecular genetic analysis to better understand disease pathogenesis and develop new prognostic models and targeted therapies. Progress expected from genomic and proteomic studies may improve our ability to develop active treatments, which may in turn improve the outcome for patients.
New therapeutic approaches and the incorporation of novel agents into these therapeutic regimens are necessary to improve the outcome of T-cell lymphomas. Gemcitabine is one of the most effective drug in PTCLU and MF; it has been active both as a single agent [10, 14] and in combination with other conventional antiblastic drugs [15] [16] [17] [18] . In addition, combination of gemcitabine with a new other compound, pralatrexate, is currently being explored in a phase I/II clinical trial [23] .
The addition of the anti-CD20 mAb rituximab to chemotherapy regimens like combination chemotherapy with cyclophosphamide, adriamycin, vincristine, and prednisone has significantly improved treatment outcomes in B-cell lymphomas. As such, several mAbs are currently being tested in PTCLU, including alemtuzumab, iratumumab, siplizumab, and zanolimumab [24] [25] [26] [27] .
There are drugs such as proteasome inhibitors [28] , histone deacetylase inhibitors [29, 30] , and folate analogues [31] original article Annals of Oncology currently being evaluated in clinical trials and their preliminary data have shown promising single-agent activity in MF patients; at the same time, folate analogues showed interesting results on PTCLU [32] in a multicentre phase II trial. The real problem of several phase II studies with new agents in rare disease like T-cell lymphomas is the update of the preliminary results in terms of duration of the response. This concept can play a pivotal role in improving our ability to develop active multiagent treatments. Our update on the role of gemcitabine as a single agent in pretreated T-cell lymphoma patients lead us to conclude that this drug has a substantial activity with acceptable toxicity and, in particular, it indicates a good quality of the response, since 7 of 39 (18%) patients are CCRs with a median time of 34 months. This post hoc subset analysis provides evidence for the long-term clinical benefit of gemcitabine in heavily pretreated PTCLU and MF, regardless of prior treatment failures.
Further studies will help to establish the clinical significance of these results and elicit the best use of this compound, either as a single agent or in combination with others. references
